The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
申请人:Shijiazhuang Sagacity New Drug
Development Company, Ltd.
公开号:EP3875460A1
公开(公告)日:2021-09-08
A pyrimidopyrazolone derivative as a Weel inhibitor and use thereof in preparation of a medicament for treating Weel-related diseases. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.
[EN] PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF<br/>[FR] DÉRIVÉ DE PYRIMIDOPYRAZOLONE EN TANT QU'INHIBITEUR DE WEE1 ET SON UTILISATION<br/>[ZH] 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用